Form 8-K - Current report:
SEC Accession No. 0001193125-20-054118
Filing Date
2020-02-28
Accepted
2020-02-28 07:16:15
Documents
14
Period of Report
2020-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d871994d8k.htm   iXBRL 8-K 28125
2 EX-99.1 d871994dex991.htm EX-99.1 52348
6 GRAPHIC g871994g99t21.jpg GRAPHIC 25154
  Complete submission text file 0001193125-20-054118.txt   244460

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sgmo-20200228.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sgmo-20200228_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sgmo-20200228_pre.xml EX-101.PRE 10950
9 EXTRACTED XBRL INSTANCE DOCUMENT d871994d8k_htm.xml XML 3281
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 20665625
SIC: 2836 Biological Products, (No Diagnostic Substances)